Infectious Diseases Society of America
Arlington, Virginia | |
Location |
|
---|---|
Membership | 13,000 as of 2023 |
President | Steven K. Schmitt, MD, FIDSA[1] |
President-Elect | Tina Tan, MD, FIDSA, FPIDS, FAAP[1] |
Website | www |
The Infectious Diseases Society of America (IDSA) is a medical association representing physicians, scientists, and other healthcare professionals who specialize in
History
The IDSA was formed from two different groups.
Publications and activities
IDSA publishes the following medical journals:
- Clinical Infectious Diseases (Clinical Infectious Diseases | Oxford Academic)
- The Journal of Infectious Diseases (The Journal of Infectious Diseases | Oxford Academic)
- Open Forum Infectious Diseases (Open Forum Infectious Diseases | Oxford Academic)
The IDSA holds an annual meeting featuring presentations by experts in various aspects of infectious diseases, as well as original research abstracts and panel discussions.
Support for the Prevention and Public Health Fund
On November 3, 2017, the U.S. House passed a bill, H.R. 3922 (the "CHAMPIONING Healthy Kids Act") that cuts $6.35 billion from the Prevention and Public Health Fund (PPHF). Paul Auwaerter, then-president of IDSA, said that the cut would hurt both public health and national security. The PPHF fund comprises over 12 percent of the budget of the Centers for Disease Control and Prevention (CDC). Auwaerter said, "…a significant cut to the fund will have a very troubling impact on CDC efforts to prevent infections and respond to outbreaks in communities and health care settings."[8]
The PPHF was created under the
Several organizations such as the American Heart Association and American Lung Association joined the IDSA in opposing the cuts.[8]
Combatting Antimicrobial Resistance
The World Health Organization has identified antimicrobial resistance as one of the three greatest threats to human health.[9] IDSA has identified antimicrobial resistance as a priority for the organization.
In 2010, IDSA launched the 10 x '20 Initiative, which seeks a global commitment to create an antibiotic research and development enterprise powerful enough to produce 10 new systemic antibiotics by the year 2020. The initiative was launched as a response to the growing problem of
According to IDSA, new antibiotic development has slowed to a standstill due to market failure and regulatory disincentives. Antibiotics aren't as profitable as other drugs (e.g., drugs to treat chronic conditions such as diabetes or asthma, which patients take for years). Also, the U.S. Food and Drug Administration (FDA) has long delayed publishing workable guidance describing how companies should design antibiotic clinical trials. Moreover, once a new antibiotic makes it to market, physicians hold it in reserve for only the worst cases rather than rushing to use it on all their patients due to fear of drug resistance. These economic and regulatory disincentives have made it far too difficult for companies to continue developing new antibiotics. It is estimated that the cost to the U.S. health care system of antibiotic resistant infections is $21 billion to $34 billion each year and more than 8 million additional hospital days.[11]
On May 1, 2011, IDSA published a policy paper titled "Combating Antimicrobial Resistance: Policy Recommendations to Save Lives" in Clinical Infectious Diseases.[12] The paper detailed the organization's recommendations for specific public policy strategies and research activities needed to promote the best interests of patients and health care professionals. Specifically, the paper urged creation of incentives to support antibiotic research and development; new rapid diagnostic tests to more quickly diagnose patients; greater coordination of government agencies to support surveillance, data collection, research, and prevention and control; and aggressive promotion of the judicious use of currently available antibiotics. IDSA's policy paper also proposed the creation of an Antimicrobial Innovation and Conservation (AIC) Fee that would help pay for antibiotic R&D and stewardship efforts necessary to make progress against antibiotic resistance.[13]
Throughout 2012, IDSA garnered support of several medical organizations and pharmaceutical companies for a new FDA approval pathway, called the Limited Population Antibacterial Drug mechanism, to address an unmet medical need by speeding up development of antibiotics to treat patients who have serious infections for which therapeutic options are insufficient. The LPAD mechanism would allow for testing a drug's safety and effectiveness in smaller, shorter, and less expensive clinical trials, similar to the Orphan Drug Program.[14]
In addition to the 10 x '20 Initiative, IDSA supports legislative and administrative efforts to strengthen the U.S. response to antimicrobial resistance, such as enhanced coordination and leadership, surveillance, prevention and control, and research efforts. IDSA also promotes the establishment of antimicrobial stewardship programs and integration of good stewardship practices in every health care facility across the United States and is working to eliminate inappropriate uses of antibiotics in food, animals and other aspects of agriculture.[15]
In a followed up policy report released on April 17, 2013, titled "10 X '20 Progress – Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America", IDSA expressed grave concern over the weak pipeline of antibiotics to combat the growing ability of bacteria, especially the
In 2018, the IDSA put out a new statement about antibiotic research. Low financial returns on antibiotic research caused stock prices to go down, and companies had abandoned antibiotic research and development. In turn, this put pressure on the few remaining companies to deliver new antibiotics. The IDSA proposed that the government create incentives that reward and support private sector work toward a "robust, renewable antibiotic supply."[17]
Lyme disease treatment guidelines
Since 2000, IDSA has recommended against long-term antibiotic treatment for
In 2006,
Pursuant to their agreement with Blumenthal, the IDSA guidelines were reviewed by an independent panel subject to strict conflict-of-interest guidelines and vetted by a medical ethicist. The panel unanimously supported the original IDSA guidelines, finding that "chronic Lyme disease" and "post Lyme syndrome" lack clear definitions and convincing biological evidence. Further, the report emphasized that several prospective clinical trials of prolonged antibiotic therapy for persistently symptomatic patients uniformly showed evidence of harm without convincing evidence of benefit.[29][30]
References
- ^ a b "Board of Directors". Infectious Diseases Society of America. Archived from the original on 8 February 2023. Retrieved 31 January 2024.
- ^ "Forming The Society". www.idsociety.org. Archived from the original on 2019-05-04. Retrieved 2019-06-16.
- ^ "IRS Form 990 for 2018" (PDF). idsociety.org. Archived (PDF) from the original on December 26, 2019. Retrieved December 26, 2019.
- ^ IDSA history Archived 2016-11-26 at the Wayback Machine – Retrieved 2017-01-25
- ^ "IDSA Meeting Website". Infectious Diseases Society of America. Archived from the original on January 30, 2012. Retrieved January 20, 2012.
- ^ "Facts About IDSA". Infectious Diseases Society of America. Archived from the original on July 26, 2011. Retrieved October 29, 2010.
- ^ "Emerging Infections Network". Emerging Infections Network. IDSA. Archived from the original on 1 July 2014. Retrieved 4 June 2014.
- ^ a b c Williams, Terri (2017-11-29). "Steep cuts to Prevention and Public Health Fund as part of House bill draws concerns". Homeland Preparedness News. Archived from the original on 2021-01-17. Retrieved 2017-12-04.
- ^ Sinha, Vidushi (May 17, 2010). "Antibiotic Resistance Called Growing Threat to Human Health". Voice of America News. Archived from the original on September 25, 2012. Retrieved December 12, 2012.
- ^ "Antibiotic Development: The 10 x '20 Initiative". Infectious Diseases Society of America. Archived from the original on December 30, 2012. Retrieved December 12, 2012.
- ^ "Facts about Antibiotic Resistance". Infectious Diseases Society of America. Archived from the original on January 3, 2013. Retrieved December 12, 2012.
- PMID 21474585.)
{{cite journal}}
: CS1 maint: multiple names: authors list (link - ^ "Combating Antimicrobial Resistance: Policy Recommendations to Save Lives" (PDF). Infectious Diseases Society of America. Archived from the original (PDF) on March 16, 2014. Retrieved May 30, 2012.
- ^ "Drug Companies, Health Groups Back IDSA Proposal" (Press release). Infectious Diseases Society of America. April 12, 2012. Archived from the original on August 26, 2012. Retrieved August 12, 2012.
- ^ "Antimicrobial Resistance". Infectious Diseases Society of America. Archived from the original on May 27, 2012. Retrieved May 30, 2012.
- ^ PMID 23599308.
- ^ "Fewer companies support antibiotic drug research, development". Homeland Preparedness News. 2018-11-27. Archived from the original on 2021-02-26. Retrieved 2018-11-30.
- PMID 17029130.
- PMID 34256207.
- from the original on 2009-08-04. Retrieved 2010-03-09.
- ^ ""Chronic Lyme Disease" Fact Sheet". National Institute of Allergy and Infectious Diseases. April 17, 2009. Archived from the original on March 8, 2010.
- ^ "Post-Treatment Lyme Disease Syndrome". Centers for Disease Control and Prevention. 2019-11-08. Archived from the original on 2017-06-17. Retrieved 9 June 2021.
- ^ O'Connell, Sue. "Recommendations for diagnosis and treatment of Lyme borreliosis: guidelines and consensus papers guidelines and consensus papers from specialist societies and ex from specialist societies and expert groups in pert groups in Europe and North America Europe and North America" (PDF). Archived (PDF) from the original on 21 January 2022. Retrieved 9 June 2021.
- PMID 17914043.)
{{cite journal}}
: CS1 maint: multiple names: authors list (link - ^ Forbes. Archived from the originalon 2007-05-03. Retrieved 2008-06-24.
- ^ a b Landers, Susan J (2008-06-09). "Lyme treatment accord ends antitrust probe". American Medical News. Archived from the original on 2008-06-11. Retrieved 2008-06-24.
- PMID 18821849.
- PMID 19211474.
- ^ "IDSA Final Report of the Lyme Disease Review Panel of the Infectious diseases Society of America". Archived from the original on 2012-06-29. Retrieved 2012-07-20.
- ^ "Special Review Panel Unanimously Upholds Lyme Disease Treatment Guidelines". Infectious Diseases Society of America. 22 April 2010. Archived from the original on 9 June 2021. Retrieved 9 June 2021.